GLP-1 drugs show lower obesity-related cancer risk than insulin, but not all diabetes treatments
Years of research point to obesity and type 2 diabetes raising the risk of developing several types of cancer. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a recent medical breakthrough, were originally developed for blood sugar control or diabetes management and also work overtime promoting weight loss. Scientists are curious to explore whether there are any links between these drugs…
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
